Terms: = Endocrine gland cancer AND CDKN2C, P42773, 1031, ENSG00000123080, INK4C, p18, p18-INK4C AND Treatment
23 results:
1. All-Cause and Cause-Specific Mortality Among Low-Risk Differentiated Thyroid cancer Survivors in the United States.
Tran TV; Schonfeld SJ; Pasqual E; Haymart MR; Morton LM; Kitahara CM
Thyroid; 2024 Feb; 34(2):215-224. PubMed ID: 38149602
[No Abstract] [Full Text] [Related]
2. The Novel Use of IL-28 as an Effective Radiosensitizer in Pancreatic cancer.
Chen X; Lee HY; Tang TT; Qin C; Prissel SA; Nelson CJ; Smith LA; Xiao H; Bai Q; Nicholl MB; Wakefield MR; Fang Y
Anticancer Res; 2023 May; 43(5):1885-1890. PubMed ID: 37097692
[TBL] [Abstract] [Full Text] [Related]
3. Utilization of chemoradiation therapy provides strongest protective effect for avoidance of postoperative pancreatic fistula following pancreaticoduodenectomy: A NSQIP analysis.
Mangieri CW; Strode MA; Moaven O; Clark CJ; Shen P
J Surg Oncol; 2020 Dec; 122(8):1604-1611. PubMed ID: 32935353
[TBL] [Abstract] [Full Text] [Related]
4. The CCR5 antagonist maraviroc causes remission of pancreatic cancer liver metastasis in nude rats based on cell cycle inhibition and apoptosis induction.
Huang H; Zepp M; Georges RB; Jarahian M; Kazemi M; Eyol E; Berger MR
Cancer Lett; 2020 Apr; 474():82-93. PubMed ID: 31954769
[TBL] [Abstract] [Full Text] [Related]
5. Rosiglitazone ameliorates senescence and promotes apoptosis in ovarian cancer induced by olaparib.
Wang Z; Gao J; Ohno Y; Liu H; Xu C
Cancer Chemother Pharmacol; 2020 Feb; 85(2):273-284. PubMed ID: 31907647
[TBL] [Abstract] [Full Text] [Related]
6. Novel use of a Clinical Laboratory Improvements Amendments (CLIA)-certified Cyclin-Dependent Kinase N2C (cdkn2c) loss assay in sporadic medullary thyroid carcinoma.
Maxwell JE; Gule-Monroe MK; Subbiah V; Hu M; Perrier ND; Cabanillas ME; Lee JE; Graham PH; Cote GJ; Busaidy NL; Grubbs EG
Surgery; 2020 Jan; 167(1):80-86. PubMed ID: 31648931
[TBL] [Abstract] [Full Text] [Related]
7. Genome-scale CRISPR/Cas9 screen determines factors modulating sensitivity to ProTide NUC-1031.
Sarr A; Bré J; Um IH; Chan TH; Mullen P; Harrison DJ; Reynolds PA
Sci Rep; 2019 May; 9(1):7643. PubMed ID: 31113993
[TBL] [Abstract] [Full Text] [Related]
8. Parathyroid Carcinoma.
Cetani F; Pardi E; Marcocci C
Front Horm Res; 2019; 51():63-76. PubMed ID: 30641523
[TBL] [Abstract] [Full Text] [Related]
9. Pre-diagnosis and post-diagnosis use of common analgesics and ovarian cancer prognosis (NHS/NHSII): a cohort study.
Merritt MA; Rice MS; Barnard ME; Hankinson SE; Matulonis UA; Poole EM; Tworoger SS
Lancet Oncol; 2018 Aug; 19(8):1107-1116. PubMed ID: 30029888
[TBL] [Abstract] [Full Text] [Related]
10. Clinical analysis of cervical lymph node metastasis risk factors in patients with papillary thyroid microcarcinoma.
Luo Y; Zhao Y; Chen K; Shen J; Shi J; Lu S; Lei J; Li Z; Luo D
J Endocrinol Invest; 2019 Feb; 42(2):227-236. PubMed ID: 29876836
[TBL] [Abstract] [Full Text] [Related]
11. Long-term results of fertility-sparing treatment compared with standard radical surgery for early-stage epithelial ovarian cancer.
Fruscio R; Ceppi L; Corso S; Galli F; Dell'Anna T; Dell'Orto F; Giuliani D; Garbi A; Chiari S; Mangioni C; Milani R; Floriani I; Colombo N; Bonazzi CM
Br J Cancer; 2016 Sep; 115(6):641-8. PubMed ID: 27537385
[TBL] [Abstract] [Full Text] [Related]
12. (Ir)relevance of Metformin treatment in Patients with Metastatic Pancreatic cancer: An Open-Label, Randomized Phase II Trial.
Reni M; Dugnani E; Cereda S; Belli C; Balzano G; Nicoletti R; Liberati D; Pasquale V; Scavini M; Maggiora P; Sordi V; Lampasona V; Ceraulo D; Di Terlizzi G; Doglioni C; Falconi M; Piemonti L
Clin Cancer Res; 2016 Mar; 22(5):1076-85. PubMed ID: 26459175
[TBL] [Abstract] [Full Text] [Related]
13. Metastases of pancreatic adenocarcinoma: A systematic review of literature and a new functional concept.
Cannistrà M; Ruggiero M; Zullo A; Serafini S; Grande R; Nardo B
Int J Surg; 2015 Sep; 21 Suppl 1():S15-21. PubMed ID: 26123383
[TBL] [Abstract] [Full Text] [Related]
14. Whole-genome sequencing of an aggressive BRAF wild-type papillary thyroid cancer identified EML4-ALK translocation as a therapeutic target.
Demeure MJ; Aziz M; Rosenberg R; Gurley SD; Bussey KJ; Carpten JD
World J Surg; 2014 Jun; 38(6):1296-305. PubMed ID: 24633422
[TBL] [Abstract] [Full Text] [Related]
15. Cell cycle deregulation and TP53 and RAS mutations are major events in poorly differentiated and undifferentiated thyroid carcinomas.
Pita JM; Figueiredo IF; Moura MM; Leite V; Cavaco BM
J Clin Endocrinol Metab; 2014 Mar; 99(3):E497-507. PubMed ID: 24423316
[TBL] [Abstract] [Full Text] [Related]
16. Medullary thyroid carcinoma: long-term outcomes of surgical treatment.
Abraham DT; Low TH; Messina M; Jackson N; Gill A; Chou AS; Delbridge L; Learoyd D; Robinson BG; Sidhu S; Sywak M
Ann Surg Oncol; 2011 Jan; 18(1):219-25. PubMed ID: 20878247
[TBL] [Abstract] [Full Text] [Related]
17. Transcriptional activation of the mixed lineage leukemia-p27Kip1 pathway by a somatostatin analogue.
Horiguchi K; Yamada M; Satoh T; Hashimoto K; Hirato J; Tosaka M; Yamada S; Mori M
Clin Cancer Res; 2009 Apr; 15(8):2620-9. PubMed ID: 19318494
[TBL] [Abstract] [Full Text] [Related]
18. KRAS or BRAF mutation status is a useful predictor of sensitivity to MEK inhibition in ovarian cancer.
Nakayama N; Nakayama K; Yeasmin S; Ishibashi M; Katagiri A; Iida K; Fukumoto M; Miyazaki K
Br J Cancer; 2008 Dec; 99(12):2020-8. PubMed ID: 19018267
[TBL] [Abstract] [Full Text] [Related]
19. Value of the cervical compartments in the surgical treatment of papillary thyroid carcinoma.
Goropoulos A; Karamoshos K; Christodoulou A; Ntitsias T; Paulou K; Samaras A; Xirou P; Efstratiou I
World J Surg; 2004 Dec; 28(12):1275-81. PubMed ID: 15517478
[TBL] [Abstract] [Full Text] [Related]
20. Mature results of a randomized trial of two doses of cisplatin for the treatment of ovarian cancer. Scottish Gynecology cancer Trials Group.
Kaye SB; Paul J; Cassidy J; Lewis CR; Duncan ID; Gordon HK; Kitchener HC; Cruickshank DJ; Atkinson RJ; Soukop M; Rankin EM; Davis JA; Reed NS; Crawford SM; MacLean A; Parkin D; Sarkar TK; Kennedy J; Symonds RP
J Clin Oncol; 1996 Jul; 14(7):2113-9. PubMed ID: 8683244
[TBL] [Abstract] [Full Text] [Related]
[Next]
